Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHaifaa AbdulhaqJRJames Relf

Discussion

Loading...

Member takes

Overview

Observational analysis shows the CRS-RS.5p model predicts severe cytokine release syndrome in patients with R/R DLBCL, highlighting its clinical utility.

Key Points

  • Cytokine release syndrome occurred in 35.5% of patients treated with glofitamab, especially within 24 hours of the first dose.
  • The CRS-RS.5p model accurately predicted Grade ≥2 CRS with a 67% true positive rate in the overall population.
  • Multivariate analysis using baseline factors including lactate dehydrogenase and white blood cell counts assessed associated risks stemming from glofitamab treatment.
  • Risk stratification may enable improved monitoring strategies in patients deemed at high risk for adverse events following treatment.

Cite This Study

Abdulhaq et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d982https://doi.org/10.1182/blood-2025-2559
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience2025
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience2025
  5. 5Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025